{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4Mjasq8IDA","lastupdate":"2021-07-27T00:00:00.000Z","update_date":"2021-07-27T00:00:00.000Z","lastModified":"Mar 19, 2024","active":1,"confidence_score":88,"confidence_score_reason":"video or image, news, markets, not claimed","urlname":"levation-pharma","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$Kh30pKaEn73WmOXYAvBPM8CRbTOLZ6DIb0bmlWxZgxe5ew7ZbRreeN","name":"Levation Pharma","oneliner":"Topical Oxymetazoline for Cosmetic Eye Lifts","registrar":"515723658","website":"https://www.levationpharma.com/","careerspage":"","founded_month":9,"founded_year":2017,"formernames":[],"sociallinks":{"twitter":"","youtube":"","facebook":"","linkedin":"https://www.linkedin.com/company/90570479","instagram":""},"social":["https://www.linkedin.com/company/90570479"],"flattenedsociallinks":"https://www.linkedin.com/company/90570479","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":null,"employees":"1-10","employees_exact":2,"patent":1,"raised":1930000,"stage":"Seed","public_stage":"Seed","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":[""],"about":"Levation Pharma is an Israeli-American company that is relating to the treatment of Acquired Blepharoptosis. Acquired Blepharoptosis is a condition in which the upper eyelids droop. Though this condition is occasionally seen in association with serious diseases, the majority of patients develop the condition as part of the natural aging process. Some patients with this condition may complain of reduced vision.\n\nThe company developed LEV-102, a proprietary odorless, colorless, rapidly drying aqueous gel. It is intended to be applied in small volume to the upper lids, similar to eyeshadow. For patients who also use eyeshadow for cosmetic purposes, LEV-102 is designed to function as an eyeshadow primer. The active pharmaceutical ingredient in LEV-102 is a drug called oxymetazoline. The gel also has stabilizers and permeation enhancers. LEV-102 is designed so that the oxymetazoline can penetrate the upper lid and reach the tiny involuntary ‘fight or flight’ muscle in the lid called Mueller’s muscle. The drug then binds to the muscle and triggers a slight contraction that is designed to lift the upper lid in a similar manner to what one might see if a person is suddenly startled.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"","country":null,"address":{"israeli":[{"id":"15f3a385-af47-4f65-9550-e4b5e94192be","city":"Tel Aviv-Yafo","type":null,"address":"Rothschild Boulevard 45, Tel Aviv-Yafo, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"Center District","news":[{"id":"y2HOLCFn1xt6XevahjKvcXQ15HDHnrKX2ZLxgiWKrfMljux95hLTDS","date":"Feb 26, 2023","link":"https://www.globenewswire.com/news-release/2023/02/27/2616041/0/en/Levation-Pharma-Initiates-Phase-I-II-Clinical-Trial-of-LEV102-for-Acquired-Blepharoptosis.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"FDA Clearance, Clinical Trial","company":"Levation Pharma","layoffs":"Not Mentioned","summary":"Levation Pharma, a pharmaceutical company specializing in ophthalmology and aesthetic therapeutics, has received FDA clearance to initiate a Phase I/II clinical trial for LEV102, a treatment for Acquired Blepharoptosis in adults. The condition, characterized by drooping of the upper eyelid, can impair vision and give an appearance of aging and tiredness. LEV102 is a proprietary aqueous gel that includes oxymetazoline as the active ingredient, intended to activate receptors on Mueller’s muscle in the upper lid. The clinical trial aims to determine preliminary safety and efficacy signals for LEV102. Levation Pharma is an Israeli-American company based in Los Angeles and is backed by venture firms Pontifax and Peregrine.","partners":"Not Mentioned","customers":"Not Mentioned","investors":["Pontifax","Peregrine"],"confidence":9,"key_topics":["FDA Clearance","Clinical Trial","LEV102","Acquired Blepharoptosis","Investment"],"date_of_event":"February 27, 2023","valuation_amount":"Not Mentioned","impact_on_company":"Growth-Positive","investment_amount":"Not Mentioned","structured_issues":["Investment"],"acquisition_amount":"Not Mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"gNVT0eL5LhiJJmNANxpoFtWhLJXwyQck6GuHADpYj8UD206h9Q2GHl","news_summary":"Levation Pharma Initiates Phase I/II Clinical Trial of LEV102 for Acquired Blepharoptosis","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":1,"techcommunityinvolvement":null,"mediagallery":[],"tags":["drug-discovery","eye-diseases","pharmaceuticals","topical-treatment","ophthalmology"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Nvx3J0IDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"Clinical Trial","products":["LEV-102"],"geomarkets":[],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":2,"lastfunding":"$1.93M","totalrounds":1,"fundingstage":"Seed","totalfunding":"$1.93M","publicinvestors":2,"lastpublicfunding":1930000,"totalpublicrounds":1,"totalpublicfunding":1930000},"team":[{"name":"Houman David Hemmati MD, PhD","email":"houmanhemmati@gmail.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4IiOot4IDA","bounced":false,"claimed":0,"founder":1,"urlname":"houman-david-hemmati-md-phd","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgqM-3hgoM","position":"Co-Founder & Chief Scientific Officer ","last_name":"Hemmati MD, PhD","claimtoken":"dda6bc6a82537a937e8ae7697e4896af5b330c8482ad76b90508a444092e405f","first_name":"Houman David","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/houman-david-hemmati-md-phd-aa0486/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2019-03-18 15:54:43.000000","initials":"HH","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":0,"tag_line_edited":0,"sector":"Pharmaceuticals","sectorverify":null,"biverify":{"id":"c9EsgAuuvwml0IzyIKWmOxLUUF5GjptiIXjHR1tp2gTB0O2GoGTfCd","fullname":"Yanina Wainscheinker"},"biverifydate":"2024-03-19T00:00:00.000Z","crunchbaseid":"","lastupdator":"Yotam Maman","lastupdator_email":"yotamm1988@gmail.com","creator":"Jenny Sotnik-Talisman","creator_email":"genys30@yahoo.com","createdate":"2019-03-18T00:00:00.000Z","biverification":"Yanina Wainscheinker","sectorverification":null,"affiliatedOrganizations":null,"timeline":[{"id":"lry59U4zMt5lDmmwzCxOK9Ky1PownYC0VBJb2br83VADO7ehJYc0fC","date":"Jun 2022","amount":"$1.93M","source":"","eventtype":"FundingRoundEvent","investment":[{"name":"Peregrine Ventures","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/peregrine-ventures","logokey":"$T9b3MhmeKbyWXOhmHsdeo59IpRH5j3rFLwfog4x6rVvePI0vqruN3t","tagline":null,"urlname":"/investor_page/peregrine-ventures","isisraeli":1,"investorid":"Y57DaSxuoKU94wasDhLnfv7mvfy2Gyr9ekuOlM6BCGtWak5CprFY2M","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"PhiXOx0Zxfr4fUH9P0mI5Ft8CinPWf293p3ry6XzRBrP9wFLNjmdzd","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$T9b3MhmeKbyWXOhmHsdeo59IpRH5j3rFLwfog4x6rVvePI0vqruN3t","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"Lead ","followupcaption":""},{"name":"Pontifax","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/Pontifax","logokey":"$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","tagline":null,"urlname":"/investor_page/Pontifax","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgOfWjoAKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"b3T0g5B574FRimmT7yOPODgnVp7zS5kNy0ogisNY8UJfQsTG4fH1yp","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":1930000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"9/2017","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Levation Pharma","logourl":"https://storage.googleapis.com/clean-finder-353810/$Kh30pKaEn73WmOXYAvBPM8CRbTOLZ6DIb0bmlWxZgxe5ew7ZbRreeN","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$Kh30pKaEn73WmOXYAvBPM8CRbTOLZ6DIb0bmlWxZgxe5ew7ZbRreeN","seoabout":"Levation Pharma is an Israeli-American company that is relating to the treatment of Acquired Blepharoptosis. Acquired Blepharoptosis is a condition in whic...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":1,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"},{"depth":3,"name":"Cosmetics","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Nvx3J0IDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Cosmetics#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Nvx3J0IDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Cosmetics#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Nvx3J0IDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"},{"title":"Cosmetics","key":"0-0-0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Cosmetics"}]}]}],"coreTechnology":[]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"},{"depth":3,"name":"Cosmetics","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Nvx3J0IDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development"],"coreTechnology":[],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Pharmaceuticals","Cosmetics"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"lry59U4zMt5lDmmwzCxOK9Ky1PownYC0VBJb2br83VADO7ehJYc0fC","date":"Jun 2022","amount":"$1.93M","source":"","eventtype":"FundingRoundEvent","investment":[{"name":"Peregrine Ventures","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/peregrine-ventures","logokey":"$T9b3MhmeKbyWXOhmHsdeo59IpRH5j3rFLwfog4x6rVvePI0vqruN3t","tagline":null,"urlname":"/investor_page/peregrine-ventures","isisraeli":1,"investorid":"Y57DaSxuoKU94wasDhLnfv7mvfy2Gyr9ekuOlM6BCGtWak5CprFY2M","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"PhiXOx0Zxfr4fUH9P0mI5Ft8CinPWf293p3ry6XzRBrP9wFLNjmdzd","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$T9b3MhmeKbyWXOhmHsdeo59IpRH5j3rFLwfog4x6rVvePI0vqruN3t","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"Lead ","followupcaption":""},{"name":"Pontifax","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/Pontifax","logokey":"$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","tagline":null,"urlname":"/investor_page/Pontifax","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgOfWjoAKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"b3T0g5B574FRimmT7yOPODgnVp7zS5kNy0ogisNY8UJfQsTG4fH1yp","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":1930000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}